Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
Provided By GlobeNewswire
Last update: Oct 21, 2025
Upon Approval of NDA Quoin Will Receive Seven Years Marketing Exclusivity for QRX003 in the US
Orphan Drug Designation previously granted by the European Medicines Agency in May 2025
Read more at globenewswire.comNASDAQ:QNRX (11/28/2025, 7:56:30 PM)
21.75
+1.03 (+4.97%)
Find more stocks in the Stock Screener
QNRX Latest News and Analysis
